Drug Type Small molecule drug |
Synonyms Risovalisib + [2] |
Target |
Mechanism PI3Kα inhibitors(Phosphatidylinositol 3 kinase alpha inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Molecular FormulaC25H33F3N8O8S2 |
InChIKeyCYWUJTNXNJVGLY-UHFFFAOYSA-N |
CAS Registry1494684-33-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
PIK3CA-related overgrowth syndrome | Phase 2 | CN | 09 May 2023 | |
PIK3CA-related vascular malformations | Phase 2 | CN | 09 May 2023 | |
Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | CN | 12 Jul 2022 | |
Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | CN | 12 Jul 2022 | |
Ovarian clear cell carcinoma | Phase 2 | JP | 13 Aug 2021 | |
Ovarian clear cell carcinoma | Phase 2 | CN | 13 Aug 2021 | |
Primary clear cell peritoneal carcinoma | Phase 2 | CN | 13 Aug 2021 | |
Primary clear cell peritoneal carcinoma | Phase 2 | JP | 13 Aug 2021 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 17 May 2018 | |
Esophageal Carcinoma | Preclinical | CN | 10 May 2018 |
Phase 1 | PIK3CA mutation/HR-positive/HER2-negative Breast Cancer PIK3CA-mutated | 52 | (rdwvmgroxh) = the most common grade 1-2 TRAEs were hyperglycaemia, nausea, decreased appetite, rash, weight decreased, diarrhoea, vomiting, stomatitis, AST increased and ALT increased nimwkkfrms (cjxymspury ) View more | Positive | 24 May 2024 | ||
NCT03544905 (Pubmed) Manual | Phase 1 | PIK3CA H1047R mutant Solid Tumors PIK3CA Mutation | 51 | (overall) | (rkoytdilhu) = slsfavywpm gbhpfcbixd (pekohblyus ) View more | Positive | 16 Nov 2022 |
(patients with PIK3CA mutations) | (kzjbjjwlsr) = tcmukrimym blxmybqofr (otjidlgeax ) |